methyl 3-(4-cyano-2-(hydroxymethyl)phenyl)-3-hydroxyacrylate | 1082071-89-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: methyl 3-(4-cyano-2-(hydroxymethyl)phenyl)-3-hydroxyacrylate
• CAS: 1082071-89-3
• 化学式: C₁₂H₁₁NO₄
• 分子量: 233.224
• InChiKey: KVNFBEVPPIKNCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.12
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  90.55
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (2,4'-difluoro-3'-methylbiphenyl-3-yl)hydrazine hydrochloride 、 methyl 3-(4-cyano-2-(hydroxymethyl)phenyl)-3-hydroxyacrylate 以 乙醇 为溶剂， 反应 0.17h， 生成
  参考文献：
  名称：

  Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold

  摘要：

  The lead optimization of a novel series of benzo[a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor is reported. The chemical instability of the dihydro-benzo[a] carbazole lead 2 was successfully addressed in the design and evaluation of compounds which also demonstrated improved potency compared to 2. Members of the scaffold have been identified which are full agonists that demonstrate cellular functional potency < 50 nM. Analog 21 demonstrates equivalent efficacy in the human megakaryocyte differentiation (CFU-mega) assay compared to Eltrombopag(TM). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.077
• 作为产物：
  描述：

  5-氰基苯酞 、 sodium methylate 、 丙二酸二乙酯 以 甲醇 为溶剂， 反应 5.5h， 生成 methyl 3-(4-cyano-2-(hydroxymethyl)phenyl)-3-hydroxyacrylate
  参考文献：
  名称：

  Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold

  摘要：

  The lead optimization of a novel series of benzo[a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor is reported. The chemical instability of the dihydro-benzo[a] carbazole lead 2 was successfully addressed in the design and evaluation of compounds which also demonstrated improved potency compared to 2. Members of the scaffold have been identified which are full agonists that demonstrate cellular functional potency < 50 nM. Analog 21 demonstrates equivalent efficacy in the human megakaryocyte differentiation (CFU-mega) assay compared to Eltrombopag(TM). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.077